Fosaprepitant: all 38 studies that test it

Page 1 of 1. Open to participants first (3), then studies with results posted, then the rest; newest registration first within each.

• Broadening Antiemetics Research by Comparing the Effectiveness of Fosaprepitant and MetoclopramideNot yet recruitingNCT06740812Phase 4
• Antiemetic Fosaprepitant To Remedy Nausea and VomitingRecruitingNCT06382012Phase 2/3
• Triple Therapy of Dexamethasone, Palonosetron, and Fosaprepitant As PONV PreventionEnrolling by invitationNCT05773950Not applicable
• Safety of a Three-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-045)CompletedNCT04054193Phase 4Results posted
• Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic ChemotherapyCompletedNCT03578081Phase 3Results posted
• Low Dose Aprepitant for Patients Receiving CarboplatinTerminatedNCT03237611Phase 2Results posted
• Effect of Fosaprepitant on Motor Evoked and Somatosensory Evoked Potentials Under General AnesthesiaCompletedNCT03197064Phase 4Results posted
• Efficacy and Safety Study of Fosaprepitant (MK-0517) Plus Ondansetron Versus Ondansetron Alone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-044)TerminatedNCT02519842Phase 3Results posted
• Fosaprepitant for N/V With High-dose Interleukin-2 for Metastatic Melanoma and Renal Cell CarcinomaTerminatedNCT01874119Phase 2Results posted
• Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Germ Cell TumorsCompletedNCT01736917Phase 2Results posted
• Study of the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children (MK-0517-029)CompletedNCT01697579Phase 2Results posted
• Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031)CompletedNCT01594749Phase 3Results posted
• Fosaprepitant Dimeglumine in Preventing Nausea and Vomiting in Patients With Gastrointestinal Cancer Receiving Combination ChemotherapyCompletedNCT01504711Not applicableResults posted
• Fosaprepitant in Patients Receiving Ifosfamide-based RegimenCompletedNCT01490060Not applicableResults posted
• Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and VomitingCompletedNCT01432015Phase 4Results posted
• Fosaprepitant (MK-0517, EMEND® IV) In Salvage Treatment of Chemotherapy-Induced Vomiting (MK-0517-030)TerminatedNCT01405924Phase 2Results posted
• Aprepitant and Fosaprepitant Time-on-Target PET (Positron Emission Tomography) Study (0869-183)CompletedNCT01111851Phase 1Results posted
• Fosaprepitant Dimeglumine in Treating Patients With Nausea and Vomiting Caused By ChemotherapyTerminatedNCT01031953Phase 1/2Results posted
• A Study to Investigate the Safety and Tolerability of MK-0517 in Healthy Subjects (MK-0517-012)CompletedNCT00990821Phase 1Results posted
• A Study to Assess the Bioequivalence of Aprepitant and Fosaprepitant and the Effect of Food on Aprepitant Bioavailability (0869-165)CompletedNCT00945321Phase 1Results posted
• Fosaprepitant Dimeglumine, Palonosetron Hydrochloride, and Dexamethasone in Preventing Nausea and Vomiting Caused by Cisplatin in Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation TherapyTerminatedNCT00895245Phase 2Results posted
• A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134)TerminatedNCT00818259Phase 1Results posted
• Evaluation of Fosaprepitant (MK0517) in Single Dose Schedule (0517-017)CompletedNCT00619359Phase 3Results posted
• Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)(0869-130)(COMPLETED)CompletedNCT00337727Phase 3Results posted
• A Study to Examine the Safety and Tolerability of MK0517 for the Prevention of Post-Operative Nausea and Vomiting (0517-015)CompletedNCT00231777Phase 3Results posted
• Antiemetic Prophylaxis With Fosaprepitant and Ondansetron in Patients Undergoing Thoracic SurgeryStatus unknownNCT05881486Not applicable
• Clinical on the Safety and Efficacy of Fosaprepitant Dimeglumine for Injection in the Prevention of CINV.Status unknownNCT05755659Not applicable
• Triple Antiemetic Regimen for Chemoradiotherapy in Cervical Cancer or Nasopharyngeal CancerCompletedNCT05564286Phase 3
• Efficacy and Safety of Fosaprepitant in Preventing Chemotherapy-induced Vomiting in Children Treated With Medium and High Emetic Chemotherapeutic DrugsStatus unknownNCT05230654Not applicable
• Comparative Study of Fosaprepitant and Aprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting in Pediatric Caner PatientsStatus unknownNCT04873284Not applicable
• Fosaprepitant for the Prevention of Nausea and Emesis During Concurrent Chemoradiotherapy for Nasopharyngeal CarcinomaCompletedNCT04636632Phase 1
• Fosaprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting in Pediatric PatientsCompletedNCT04508400Phase 2
• PALONOSETRON X FOSAPREPITANT IN PONVStatus unknownNCT03586817Phase 4
• Importance of Substance P in Intracranial Pressure Elevation Following Traumatic Brain InjuryWithdrawnNCT03035838Early Phase 1
• Study Assessing Fosaprepitant in Advanced NSCLC Patients Treated With Carboplatin Based ChemotherapyStatus unknownNCT02407600Phase 2
• Fosaprepitant Dimeglumine and Granisetron Transdermal System in Preventing Nausea and Vomiting in Patients With Breast Cancer Undergoing ChemotherapyTerminatedNCT01649258Phase 1
• Study of Aprepitant / Fosaprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting (CINV) in Colorectal Cancer Patients - SENRI TrialCompletedNCT01344304Not applicable
• Efficacy of Two Antiemetic Regimens in Patients Receiving Radiotherapy and Concomitant Weekly CisplatinCompletedNCT01074697Phase 3

← Fosaprepitant overview